Navigation Links
Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
Date:6/24/2009

MORRISTOWN, N.J., June 24 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for levonorgestrel tablets, 0.75 mg, for women seventeen years and younger. Levonorgestrel is the generic equivalent to Duramed Pharmaceuticals' PLAN B(R), which is indicated for the prevention of pregnancy following unprotected intercourse or contraceptive failure. This product is approved for prescription use only. The Company intends to market the product under the trade name Next Choice(TM) and plans to launch the product shortly. For the 12-months ending March 2009, PLAN B(R) had total U.S. sales of approximately $123 million, of which approximately ten percent are attributable to prescription sales, according to IMS sales data. PLAN B(R) over-the-counter (O.T.C.) new product exclusivity expires on August 24, 2009.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.

PLAN B(R) is a registered trademark of Women's Capital Corporation, a subsidiary of Duramed Pharmaceuticals, Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson to Acquire Arrow Group
2. Watson Files FDA Application for Generic Mucinex(R) D
3. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
4. Watson-Marlow Releases Informative Video Featuring Showcased High Purity Pumps, Tubing and Fillers at Interphex 2009
5. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
6. Watson Files FDA Applications for Generic Mucinex(R)
7. Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting
8. Companies Continue To Add Wellness Programs, Watson Wyatt/National Business Group On Health Survey Finds
9. Mark G. Watson Named Executive Director of Radiological Society of North America
10. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
11. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Toledo, Ohio (PRWEB) , ... February 27, 2017 , ... Elisa Guajardo Carothers is not ... than Life” to studying to become a nun. Now, she writes about God, when she ... fiction, “You Know BC and AD, Here is BS! (Before Satan),” she offers a comedic ...
(Date:2/27/2017)... Linda, Ca (PRWEB) , ... February 27, 2017 ... ... Life Sciences, provides an overview on laser diffraction analysis as a tool to ... its capabilities, significance and potential to obtain improved results and novel scientific findings. ...
(Date:2/27/2017)... ... 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International ... the Center for Disease Control ( CDC ) and Infectious Diseases Society of America ... M.D. has compiled into a single volume a compelling argument that the disease does ...
(Date:2/27/2017)... ... 2017 , ... Sunshine Coast Health Centre (SCHC), one of ... https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a registered massage ... commitment to innovation in drug rehab and alcohol treatment strategies beyond a "punishment" ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... environs, is proud to announce an upgrade to the company's Yelp listing. Bay ... page on topics as diverse as Platelet Rich Plasma (PRP) therapy, hair transplantation ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Feb. 27, 2017 Mederi Therapeutics today ... studies, representing 2468 patients who received  Stretta Therapy  ... entitled, " Systematic Review and Meta-Analysis of Controlled ... for Treatment of Gastroesophageal Reflux Disease ", was published ... Ronnie Fass , MD, head of the Esophageal ...
(Date:2/27/2017)...   Royal Philips (NYSE: ... health technology, today announced 510(k) clearance from the ... its ElastQ Imaging capability, further expanding the functionalities ... Imaging enables simultaneous imaging of tissue and assessment ... diagnosis of various liver conditions. With ElastQ Imaging, ...
(Date:2/27/2017)... TAMPA, Fla. , Feb. 27, 2017 ... device company focused on developing cerebral embolic protection ... members of the FDA,s Circulatory System Devices Panel ... of the need for cerebral protection following transcatheter ... statements shared by this FDA panel support the ...
Breaking Medicine Technology: